Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 5.

Harrison, C F; Chiriano, G; Finsel, I; Manske, C; Hoffmann, C; Steiner, B; Kranjc, A; Pattey-Vuadens, O; Kicka, S; Trovimov, V; Ouertatani-Sakouhi, H; Soldati, T; Scapozza, L; Hilbi, H (2015). Amoebae-based screening reveals a novel family of compounds restricting intracellular Legionella. ACS Infectious Diseases, 1(7):327-338.

Wyen, C; Hendra, H; Siccardi, M; Platten, M; Jaeger, H; Harrer, T; Esser, S; Bogner, J R; Brockmeyer, N H; Bieniek, B; Rockstroh, J; Hoffmann, C; Stoehr, A; Michalik, C; Dlugay, V; Jetter, A; Knechten, H; Klinker, H; Skaletz-Rorowski, A; Fätkenheuer, G; Egan, D; Back, D J; Owen, A (2011). Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. Journal of Antimicrobial Chemotherapy, 66(9):2092-2098.

Müller, A J; Hoffmann, C; Galle, M; van den Broeke, A; Heikenwalder, M; Falter, L; Misselwitz, B; Kremer, M; Beyaert, R; Hardt, W D (2009). The S. Typhimurium effector SopE induces caspase-1 activation in stromal cells to initiate gut inflammation. Cell Host & Microbe, 6(2):125-136.

Wyen, C; Hendra, H; Vogel, M; Hoffmann, C; Knechten, H; Brockmeyer, N H; Bogner, J R; Rockstroh, J; Esser, S; Jaeger, H; Harrer, T; Mauss, S; van Lunzen, J; Skoetz, N; Jetter, A; Groneuer, C; Fätkenheuer, G; Khoo, S H; Egan, D; Back, D J; Owen, A (2008). Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 61(4):914-918.

Landovitz, R J; Angel, J B; Hoffmann, C; Horst, H; Opravil, M; Long, J; Greaves, W; Fätkenheuer, G (2008). Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. Journal of Infectious Diseases, 198(8):1113-1122.

This list was generated on Tue Nov 21 02:35:39 2017 CET.